Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

PSD-95 inhibitor

A-AA2, lys-leu-ser-ser-ile-glu-ser-asp-val-aa1 technology, applied in the field of PSD-95 inhibitors, can solve problems such as lack of treatment methods, achieve stable properties and significant protection effect of action

Inactive Publication Date: 2019-12-31
CHENGDU AODA BIOTECHNOLOGY CO LTD
View PDF3 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0002]Acute ischemic stroke is one of the diseases with the highest mortality and disability rates in the world, and currently there is no effective treatment method in clinical practice

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • PSD-95 inhibitor
  • PSD-95 inhibitor
  • PSD-95 inhibitor

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0028] Example 1 Preparation of Compound 1

[0029] Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-Lys-Leu-Ser-Ser-Ile-

[0030] Glu-Ser-Asp-Val-Lys(AEEA-AEEA-γGlu-18 alkanedioic acid)-NH 2

[0031] The preparation method includes: preparing the peptide resin by solid-phase polypeptide synthesis method, acid hydrolyzing the peptide resin to obtain a crude product, and finally purifying the crude product to obtain a pure product; wherein the step of preparing the peptide resin by the solid-phase polypeptide synthesis method is to pass solid-phase The phase-coupled synthesis method sequentially inserts the corresponding protected amino acids or fragments in the following sequences to prepare peptide resins:

[0032] In the above preparation method, the amount of the Fmoc-protected amino acid or protected amino acid fragment is 1.2-6 times of the total moles of the resin fed; preferably 2.5-3.5 times.

[0033] In the above preparation method, the substitution value of the carrier...

Embodiment 2

[0069] Example 2 Preparation of Compound 2

[0070] Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-Lys-Leu-Ser-Ser-Ile-

[0071] Glu-Ser-Asp-Val-Lys(cholesteryl succinate)-NH 2

[0072] The preparation method is the same as in Example 1, and the protected amino acids used are as follows:

[0073] The peptide sequence n= Protected Amino Acids 1 Fmoc-Lys(Alloc) 2 Fmoc-Ala 3 Fmoc-Thr(tBu) 4 Fmoc-His(Trt) 5 Fmoc-Leu 6 Fmoc-Lys(Boc) 7 Fmoc-Aib 8 Fmoc-Leu 9 Fmoc-Leu 10 Fmoc-Lys(Boc) 11 Fmoc-Glu(OtBu) 12 Fmoc-Leu 13 Fmoc-Leu 14 Fmoc-Glu(OtBu) 15 Fmoc-Arg(Pbf) 16 Fmoc-Arg(Pbf) 17 Fmoc-Arg(Pbf) 18 Fmoc-Leu 19 Fmoc-Asp(OtBu) 20 Fmoc-Gln(Trt) 21 Fmoc-Ile 22 Fmoc-Ser(tBu) sidechain-1 cholesteryl succinate

[0074] 7.7 g of pure product was obtained, the purity was 97.1%, and the total yield was 24.7%. The molecular weight is 3114.6 (100...

Embodiment 3

[0075] Example 3 Preparation of Compound 3

[0076] Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-Lys-Leu-Ser-Ser-Ile-

[0077] Glu-Ser-Asp-Val-Lys (PEG 5 CH 2 CO-γGlu-18 alkanedioic acid)-NH 2

[0078] The preparation method is the same as in Example 1, and the protected amino acids used are as follows:

[0079]

[0080]

[0081] 9.3 g of pure product was obtained, the purity was 98.7%, and the total yield was 27.8%. Molecular weight 3349.2 (100% M+H).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the field of medicine synthesis, and discloses a PSD-95 inhibitor. The PSD-95 inhibitor disclosed by the invention is used for preparing a pharmaceutical composition for treating diseases, and the pharmaceutical composition is used for preparing neuroprotective drugs after ischemic brain injury.

Description

technical field [0001] The present invention relates to a PSD-95 inhibitor and its application. Background technique [0002] Acute ischemic stroke is one of the diseases with the highest mortality rate and disability rate in the world, and there is currently no effective treatment in clinical practice. Cerebral ischemia can cause a cascade reaction from energy deprivation to cell death. Early events mainly include excitotoxicity and oxidative stress, while late events mainly include inflammation and apoptosis. At present, a large number of basic and clinical researches are devoted to the intervention of signaling molecules related to stroke pathology to develop effective neuroprotective therapy. As the initial link of stroke pathology, excitotoxicity is the primary target of stroke treatment. After cerebral ischemia, excitatory glutamate is excessively released and continues to act on N-methyl-D-aspartate (NMDA) receptors, thereby initiating a series of downstream harmful...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K14/00A61K38/16A61P9/10
CPCC07K14/001A61P9/10A61K38/00
Inventor 周述靓王鹏邓岚
Owner CHENGDU AODA BIOTECHNOLOGY CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products